The role of Src in colon cancer and its therapeutic implications
Jiezhong Chen1, Aymen Elfiky2, Mei Han3
1School of Biomedical Sciences, University of Queensland, St Lucia, Australia.
Abstract:
Src is a member of a superfamily of membrane-associated nonreceptor protein tyrosine kinases. It is stimulated by receptors of growth hormone, cytokines, and adipokines, and it regulates multiple signaling pathways, including phosphatidylinositide 3 kinase-Akt, mitogen-activated protein kinase, signal transducer and activator of transcription 3, interleukin 8, and vascular endothelial growth factor pathways, and cytoskeletal pathways to cause a cascade of cellular responses. Eighty percent of patients with colon cancer overexpress Src in tumor tissue. Evidence has shown that the overexpression of Src in colon cancer accelerates metastasis and causes chemotherapeutic drug resistance via multiple downstream signaling pathways. Therefore, the inhibition of Src may be useful for the treatment of colon cancer. However, the inhibition of Src may also weaken immune responses that are essential for the eradication of cancer cells. Overcoming the problem of inhibiting Src in cancer cells while retaining immune system efficacy is the key to the successful application of Src-inhibition therapy. Different Src family members are used by the immune system and colon cancer. This differential use may provide a good opportunity to develop Src family member-specific inhibitors to avoid immune inhibition.
Insights
Src tyrosine kinase overexpression in colon cancer drives metastasis and drug resistance. Inhibiting Src may treat cancer but harm immunity; however, targeting specific Src family members could offer a solution.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Src is a nonreceptor protein tyrosine kinase regulating cellular responses.
- Src overexpression is found in 80% of colon cancer patients.
- Elevated Src accelerates colon cancer metastasis and confers chemotherapeutic resistance.
Purpose of the Study:
- To explore the therapeutic potential of Src inhibition in colon cancer.
- To address the challenge of maintaining immune efficacy during Src inhibition therapy.
- To investigate the differential utilization of Src family members by cancer cells and the immune system.
Main Methods:
- Review of signaling pathways regulated by Src, including PI3K-Akt, MAPK, and STAT3.
- Analysis of evidence linking Src overexpression to colon cancer progression and drug resistance.
- Exploration of the potential for developing Src family member-specific inhibitors.
Main Results:
- Src signaling pathways are critical for cellular responses and cancer progression.
- Src inhibition presents a potential therapeutic strategy for colon cancer.
- Differential Src family member usage suggests a pathway for targeted therapy with reduced immunotoxicity.
Conclusions:
- Targeting Src offers a promising avenue for colon cancer treatment.
- Developing specific Src inhibitors can mitigate the risk of immunosuppression.
- Exploiting differential Src family member expression is key to effective and safe Src-targeted cancer therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:38Mitogens and the Cell Cycle
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...